Altimmune Inc (ALT)

[THREE-DAY-TRADER]

They are sufficiently funded in the short term with cash for approx 1+ Year yet or at least 11 months.
It's right there in the recent earnings report (below). Anyone can easily see it with 1 minute's worth of due diligence. Whoever said that ALT is low on cash to find operations is ignorant or has very-very high standards for funding needs.
As one of my criteria, I always make sure these biotechs have approx 1+ Year's worth of cash before I even consider it, watch it, or trade it for the short term. I also check standard loan/debt levels (excluding the share offerings/warrants), and ALT has a low loan debt level that's easily manageable, so very low risk of BK, too.

With a penny stock priced biotech, on average you're not going to get much better than 1-2 years of cash to fund operations. These biotechs typically price offerings on average annually. $ALT just did a public offering to raise cash a little while ago. &ALT is good financially in the short term. I would not be worried about more cash raising news until at least October - 4th Qtr 2018 or early Jan-Feb 2019.
If anyone cares about the longer term, then that's different, and as for me I don't associate longer term with these stocks because they're only good for short term trading. Longer Term thinking has no place wiht these stocks as they're trend long term typically is 99% of the time downward, but great for short term swing trading from oversold lows.


March 28, 2018

"Raised approximately $30 million in financing, including through a Series B preferred offering, cash acquired in connection with the reverse merger with PharmAthene and a pre-merger private placement with existing investors, providing cash into the first quarter of 2019"


https://finance.yahoo.com/news/altimmune-announces-financial-results-ended-204454692.html